Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Simulations Plus Inc (NQ: SLP )

47.95 -0.59 (-1.22%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Simulations Plus Inc

< Previous 1 2 3 4 Next >
Simulations Plus Inc. (NASDAQ: SLP) Near the Top of Equities by Percentage Gain on 4/4
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus and the University of Bath Awarded New FDA Grant
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Launches Corporate Development Initiative
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Participate in Upcoming Healthcare Conferences
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases GastroPlus® Version 9.9
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Embarks on Collaboration with Northeastern University and The TIM Company Through New FDA Grant
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports First Quarter Fiscal 2024 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Leadership Appointments Supporting Commitment to Clients and Driving Growth
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces First Quarter Fiscal Year 2024 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Outlines Paths to Win at 2023 Investor Day
From Simulations Plus, Inc.
Via Business Wire
ISoP New Board of Trustees Members Announced
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus to Host Investor Day on Tuesday, November 14th
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Fourth Quarter and Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Receives New FDA Grant Award
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Hosts First-of-its-Kind Virtual Summer Camp for Students and Professors
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Chief Science Officer Dr. Viera Lukacova Honored as Fellow by the American Association of Pharmaceutical Scientists (AAPS)
From Simulations Plus, Inc.
Via Business Wire
Researchers Use the Simulations Plus DILIsym® Platform to Predict Safety of Combined CBD and VPA Treatment
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Releases ADMET Predictor® 11
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Third Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Acquires Immunetrics to Expand its Immunology and Oncology Drug Development Capabilities
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
From Simulations Plus, Inc.
Via Business Wire
Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results
From Simulations Plus, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.